| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGUGCGGGCUGAGAAGGCGGUGGCUGCAGCAGCAGCGGCGGCGGAAACC… | 1469 nt | 0.6508 | |
| AGUGCGGGCUGAGAAGGCGGUGGCUGCAGCAGCAGCGGCGGCGGAAACC… | 1460 nt | 0.6514 |
Predicted to enable GTP binding activity and calcium channel regulator activity. Predicted to be involved in small GTPase-mediated signal transduction. Predicted to be located in T-tubule. Predicted to be active in plasma membrane. Implicated in type 2 diabetes mellitus. Biomarker of congestive heart failure. [provided by Alliance of Genome Resources, Jul 2025]
A study in humans and mice demonstrated that the RRAD is a GTPase regulating L-type Ca2+ channels and serves as a marker for molecular niche 2, which is enriched in damaged tissue areas in border zones after myocardial infarction [Kuppe et al. DOI:10.1038/s41586-022-05060-x]. It was identified as a target gene of ATF3 within the cardiomyocyte enhancer gene-regulatory network associated with the stressed vCM3 state. A study in mice demonstrated that the RRAD mRNA was down-regulated (0.31-fold) in bone marrow cells 6 hours after a 6.5 Gy whole-body ionizing radiation exposure [Dai et al. DOI:10.1080/09553000600857389].